Tekmira Pharmaceuticals (ABUS): Rasio rega marang bathi tumrap wutah

Arbutus Biopharma (ABUS) combines ownership of key LNP patents for mRNA vaccines with high authority within the scientific community. This PEG ratio chart allows for an asset valuation, where the value 0.00 represents the current indicator level. Simultaneously, Arbutus Biopharma is minimizing risks by developing comprehensive therapy methods aimed at the complete cure of patients with chronic hepatitis B.

Arbutus Biopharma Corp (ABUS): Pangali rega marang bathi tumrap wutah saka 04.07.2022 nganti 12.11.2026

Rincian metrik lan analitis perusahaan Arbutus Biopharma (ABUS)

- rega saham lan konsensus proyeksi valuasi:

Bagan owah-owahan rega Arbutus Biopharma Corp|ABUS - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Arbutus|ABUS - Nilai Perusahaan

- statistik nilai buku emiten:

Aset Bersih saben Saham Arbutus Biopharma|ABUS - Aset Bersih Perusahaan|Rasio Nilai Pasar marang Nilai Buku arbutusbio.com|ABUS - Total Aset Perusahaan

- statistik kawajiban utang lan likuiditas:

Utang marang Modal Arbutus Biopharma|ABUS - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal arbutusbio.com|ABUS - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Arbutus|ABUS - Utang jangka dawa perusahaan|Silihan lan utang jangka cendhak perusahaan Arbutus Biopharma|Likuiditas cepet arbutusbio.com

- data bathi resik lan rasio valuasi:

ABUS - Penghasilan resik|Proyeksi bathi mangsa ngarep Arbutus Biopharma|ABUS - Koefisien rega marang bathi|Rasio kapitalisasi marang bathi mangsa ngarep Tekmira Pharmaceuticals|ABUS - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Arbutus|ABUS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone patang kuartal pungkasan Arbutus Biopharma|ABUS - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan arbutusbio.com|ABUS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Arbutus Biopharma

Analisis umum perusahaan:ABUS Arbutus Biopharma Corp

To minimize risks when selecting assets, it is essential for an investor to compare a company's market value with its earnings growth rate, which allows for the identification of undervaluation at values below one. By analyzing the PEG ratio trend, one can assess how effectively the market discounts the potential of Arbutus Biopharma (ABUS), considering the monetization of its unique LNP patents through licensing agreements with pharmaceutical behemoths.

Pesaing Arbutus Biopharma

ARWR (Arrowhead Pharma) - Koefisien bali modal nimbang wutah|Rasio rega marang bathi tumrap wutah Mirum Pharma MIRM|Dynavax - Rasio rega marang bathi tumrap wutah|Inventiva S.A. - Pangali PEG|Kapitalisasi marang bathi resik kanthi nimbang wutah gyretx.com GYRE|ASMB (Assembly Biosciences, Inc.) - Pangali rega marang bathi tumrap wutah|GALT (Galectin Therapeutics Inc.) - Rasio rega marang bathi tumrap wutah|GNFT (Genfit SA) - Pangali PEG|Rega marang bathi kanthi panyesuaian wutah DURECT Corp. DRRX|Rasio rega marang bathi tumrap wutah Aligos Therapeutics (ALGS)|BIVI (biovieinc.com) - Koefisien bali modal nimbang wutah|Pangali PEG GLMD (Galmed Pharmaceuticals Ltd.)|Pangali PEG ENDRA Life Sciences Inc NDRA|HEPA - Rasio rega marang bathi tumrap wutah